Study guide
2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors
Key Takeaways Explain This Topic AI
Concurrent controls from the same protocol, strain, room, and calendar interval are the primary comparison; historical controls from the same laboratory and a recent, matched database are supporting only.
Vehicle controls receive the vehicle at the highest volume used among treated groups; corn-oil gavage itself can raise pancreatic acinar proliferative lesions and lower mononuclear-cell leukemia in male F344 rats (NTP TR-426).
Positive controls show assay sensitivity—cyclophosphamide in the mammalian erythrocyte micronucleus test; sodium azide (−S9) and 2-aminoanthracene (+S9) in Ames—and they do not replace vehicle or negative controls.
Sham surgery or air-only nose-only restraint isolates procedure stress from test-article effects; pair-feeding isolates palatability and caloric restriction from chemical toxicity.
Stratified randomization, mixed cage locations, adequate n, and treating the litter (not the fetus) as the unit in developmental studies keep housing and kinship from masquerading as treatment.
Last updated: September 2026
Every treated group is interpreted against something. Domain I.A.1 C of the DABT practice analysis (control groups and confounding factors) is where otherwise well-dosed studies fail: the “control” was the wrong procedure, the vehicle was biologically active, cages were stacked by dose, or fetuses were analyzed as if they were independent adults. Independent ExamFinch coverage here maps negative, vehicle, untreated, positive, and sham controls, then the design habits that keep those controls honest.
Concurrent versus historical controls
Concurrent controls are animals from the same protocol, strain, supplier, diet, water, room, and calendar interval as the treated groups. They are the primary statistical comparison. OECD chronic and carcinogenicity guidelines require a concurrent control. If a vehicle is used, that control receives the vehicle at the highest volume used among the dose groups, and is handled identically except for the test chemical.
Historical controls are the laboratory’s own recent control database—ideally the same strain, supplier, diet, diagnostic criteria, and a defined recent time window. They are supporting . They help when the finding is a rare tumor and the concurrent control happened to be 0/50 while the laboratory background is 0–3%; when the concurrent control looks unusually high or low (a pituitary-tumor cluster in one study); or when a statistically significant shift still sits inside ordinary biological noise. They do not replace concurrent controls. Mixing NTP, CRO A, and CRO B tables across decades, diets (NIH-07 versus NTP-2000), and diagnostic conventions is how false “within historical range” arguments are built.
Negative, vehicle, untreated, and positive controls
Control type What animals receive Why it exists Teaching example
Negative / vehicle Vehicle at the high-dose volume, no test article Isolates formulation effects from the chemical 0.5% methylcellulose gavage; corn oil; aqueous DMSO mixtures
Untreated No gavage and no vehicle Detects vehicle toxicity or procedure stress Extra untreated arm when oil gavage or frequent restraint is used
Positive A substance known to produce the endpoint Proves the assay can detect a response (sensitivity) Cyclophosphamide in OECD 474; sodium azide (−S9) and 2-AA (+S9) in OECD 471
Sham The procedure without test article, atmosphere, or implant Isolates surgery, restraint, or device-placement trauma Sham laparotomy; nose-only air-only restraint; empty pump
Vehicle effects are not hypothetical. NTP Technical Report 426 showed that chronic corn-oil gavage in male F344/N rats at 2.5, 5, and 10 mL/kg (5 days/week for 2 years) increased pancreatic acinar hyperplasia and adenoma and decreased mononuclear-cell leukemia relative to untreated controls. Safflower oil and tricaprylin produced related pancreatic findings. If the only control is untreated, oil-dosed groups can look like pancreatic carcinogens for reasons that have nothing to do with the test article. That is why a volume-matched vehicle control is required, and why an extra untreated group is sometimes added when the vehicle itself is under suspicion.
DMSO is the workhorse organic solvent in Ames tests (commonly on the order of 100 μL/plate ) but is a poor neat repeated-dose gavage vehicle: it is irritant, can dominate clinical signs, and in-life laboratories typically keep it to a small percentage of an aqueous/organic mix rather than 100% DMSO every day. Residual-solvent permitted daily exposures in finished drug product (ICH Q3C) are a manufacturing specification. They are not a license to use DMSO as the daily toxicology vehicle.
When possible, aqueous vehicles (water, saline, methylcellulose, carboxymethylcellulose) are preferred over oils. OECD TG 474 lists water, saline, methylcellulose, CMC, olive oil, and corn oil among compatible micronucleus vehicles and warns that an atypical solvent needs historical or published evidence that it does not itself raise micronuclei.
Positive controls in genetic toxicology demonstrate proficiency and, where relevant, metabolic activation. They are not a substitute for the vehicle/negative control and they are not part of a standard OECD 408 90-day general-toxicity design.
Ames (OECD 471): Sodium azide is a classic direct-acting positive control for Salmonella typhimurium TA1535 and TA100 without S9 . 2-Aminoanthracene (2-AA) is widely used with S9 to show that the exogenous activation system can convert a promutagen. Strain-specific direct-acting controls (2-nitrofluorene for TA98, 9-aminoacridine for TA1537) complete a competent panel. An Ames study whose +S9 2-AA plates look like solvent plates does not “prove the test article is non-mutagenic”; it proves the S9 mix or the method failed.
Micronucleus (OECD 474): Cyclophosphamide is a canonical in-life inducer of micronuclei (often given intraperitoneally in the positive-control arm). Mitomycin C is another. The vehicle control still anchors the spontaneous micronucleus rate against the laboratory historical range.
Sham procedures, inhalation restraint, and pair-feeding
Sham surgery belongs in protocols for implants, infusion pumps, and surgically placed devices. Otherwise adhesions, infection, analgesic effects, and postsurgical ileus are credited to the material. Sham restraint belongs in nose-only inhalation : tube restraint is stressful and can cut food intake; an air-only sham group shows what the procedure does before any test atmosphere is added. Whole-body chambers trade that restraint stress for a different confounder—animals groom deposited material and add an oral dose they were not supposed to have.
Pair-feeding is the control for palatability collapse. When high-dose dietary animals eat 30% less, they lose weight, drop thymus and liver weight, delay puberty, and look “toxic.” Pair-fed controls receive the same amount of untreated diet that the treated animals consumed. If pair-fed controls reproduce the finding, caloric restriction is in the dock, not necessarily the chemical. OECD TG 452 notes that an additional pair-fed control may be useful when reduced dietary intake is driven by palatability.
Cage location, litter effects, n, and randomization
Cage-location bias is real. Temperature, light intensity, vibration, and technician traffic differ from rack top to bottom and from the door to the back wall. If every high-dose cage sits on the top shelf under a fluorescent bank, reduced body weight or apparent phototoxicity can be housing. Randomize cage position independently of dose; some laboratories also rotate positions on a schedule written into the SOP.
Litter effects dominate developmental toxicology. In OECD TG 414 prenatal developmental studies and TG 443 extended one-generation studies, pups in a litter share genetics, maternal nutrition, and uterine position. The litter is the statistical unit , not the fetus. Treating 12 dams × 12 fetuses as n = 144 independent observations inflates false positives for fetal weight and malformations.
Sample size and randomization complete the control story. Concurrent control n should match treated groups (10/sex in OECD 408; 50/sex in OECD 451). Randomization is typically stratified by body weight so one group is not packed with runts. Without randomization, assignment order (first ten animals off the truck become controls) confounds supplier-shipping stress with treatment.
Why n matters: a beautifully randomized vehicle control with n = 3 per sex cannot distinguish a 20% ALT shift from noise. Why randomization matters: a large n allocated by cage row still estimates the row effect, not the test article.
Protocol scenario
You review a 2-year male F344 rat gavage bioassay. Treated groups received the test article in 5 mL/kg corn oil . The only control listed is “untreated.” High-dose males show an increase in pancreatic acinar adenomas (p < 0.05 versus untreated) and a decrease in mononuclear-cell leukemia. NTP oil-vehicle studies already associate those two shifts with corn oil itself. The missing vehicle control at 5 mL/kg corn oil is a design defect: you cannot separate test-article carcinogenicity from vehicle biology. Historical oil-gavage controls from the same laboratory, strain, and era can support that discussion; they cannot retroactively create the concurrent vehicle arm. A second defect on the same protocol: dose groups were housed by row on one rack. Even a correct vehicle control would not fully rescue a location confounder. The repair for the next study is mechanical: volume-matched vehicle concurrent control, body-weight-stratified randomization, rack positions mixed by dose, and historical ranges used only as supporting narrative.
A second, shorter illustration: an OECD 474 micronucleus study reports a negative test article, a quiet vehicle control, and no cyclophosphamide (or other) positive-control response . That study is uninterpretable , not reassuring. Sensitivity was not demonstrated in that experimental run.